Creative Biolabs has a tradition of commitment. To achieve efficient execution and regulatory approval, we offer careful considerations of your program for the development of a cellular or gene therapy product – now and in the future.
EXPLORE MORE HighlightsWe focus on unmet needs and develop novel cellular and gene drugs and solutions that offer significant benefits over existing options.
EXPLORE MORE HighlightsThe advent of Chimeric Antigen Receptor T-cell (CAR-T) therapies has revolutionized the field of oncology, providing new avenues for treating various forms of cancer. Our 20 years of experience in the biotechnology sector have equipped us with the expertise and technological capabilities to support the entire lifecycle of CAR-T products, from early development to commercialization.
EXPLORE MORETo accelerate advanced breakthroughs of your projects, we offer broad range of platforms which enable our clients be free to tackle problems with cutting-edge technologies from different angles and in different methods.
EXPLORE MORE HighlightsUse the resources in our library to help you understand your options and make critical decisions for your study. We offer oncolytic virus, CAR-T, and dendritic cell related documents, as well as newsletter. If you don't find the answers you're looking for, contact us for additional assistance.
EXPLORE MORE HighlightsGet a real taste and understanding of the business and culture of one of the world's great research-based cellular and gene therapy discovery and development companies.
EXPLORE MORE
In addition to scFv generation from Hybridoma cells, Creative Biolabs also provides custom one-stop CAR development solution for generating scFv from Phage display library. This scFv phage display service mainly includes library construction and screening.
Fig.1 Schematic representation of (A) scFv-displaying phage and (B) phage display procedure.1
With our excellent scientists, Creative Biolabs can establish an immunized phage display scFv library, from which a scFv against the interested antigen can be screened out. Firstly, we will design the suitable primers for cloning the antibody genes from B lymphocytes of several different species, followed by integrating the antibody genes into a phage display vector. The recombinant phagemid population will then be transformed into Escherichia coli in which they can produce phage-displayed scFv depending on the helper phage. In the last critical step, we will screen this scFv phage display library with the specific antigen from our customers or the recombinant antigen prepared ourselves. Creative Biolabs also provides molecular characterization during scFv generation such as western blot, ELISA or DNA sequencing. Creative Biolabs guarantees that our scFv phage library can achieve a capacity of over 1×1010 clones.
Depending on our various technology platforms, Creative Biolabs can offer you world-class scFv construction services, which can greatly accelerate your research progress with much lower unpredictable risk. Please do not hesitate to contact us.
Reference
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
NEWSLETTER
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTER
NEW SOLUTION
CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTION
NOVEL TECHNOLOGY
Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGY
NEW SOLUTION
Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION
